3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase NA
1
Status
Recruiting
3
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
59
Neoplasm Metastasis
5
Prostate Cancer Metastatic
3
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
3
Adenocarcinoma
3
Prostate CA
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Urologic Diseases
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stage IV Prostate Adenocarcinoma AJCC v7
1
Salivary Gland Neoplasms
1
Recurrence
1
Radiation Injuries
1
Prostatic Diseases
1
PSA Level Greater Than 0.03
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Neoplasm Recurrence, Local
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Lymphatic Metastasis
1
Intraprostatic Prostate Cancer
1
Hormone Sensitive Prostate Cancer
1
Genital Neoplasms, Male
1
Gastrointestinal Diseases
1
Interventions
Radiosurgery
3
Androgen Antagonists
3
Prednisone
2
Docetaxel
2
Abiraterone Acetate
2
fludrocortisone acetate
1
enzalutamide
1
darolutamide
1
apalutamide
1
Standard of Care
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Pluvicto
1
Midazolam
1
Lutetium-177
1
Lutetium
1
Hydrocortisone
1
Gonadotropin-Releasing Hormone
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Prostate Cancer Metastatic
×
Androgen Antagonists
×
1 year
×
Clear all
NCT04916613
2026-04-28
GETUG-AFU 40
UNICANCER
Phase 3
Recruiting
300 enrolled
NCT04983095
2026-02-17
METRO
Umeå University
Phase NA
Recruiting
118 enrolled
NCT06320067
2025-09-26
STAMPEDE2
University College, London
Phase 3
Recruiting
3,360 enrolled